Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort

Summary

Several cohort studies have investigated the molecular basis of von Willebrand disease (VWD); however, these have mostly focused on European and North American populations. This study aimed to investigate mutation spectrum in 26 index cases (IC) from Turkey diagnosed with all three VWD types, the majority (73%) with parents who were knowingly related. IC were screened for mutations using multiplex ligation-dependent probe amplification and analysis of all von Willebrand factor gene (VWF) exons and exon/intron boundaries. Selected missense mutations were expressed in vitro. Candidate VWF mutations were identified in 25 of 26 IC and included propeptide missense mutations in four IC (two resulting in type 1 and two in recessive 2A), all influencing VWF expression in vitro. Four missense mutations, a nonsense mutation and a small in-frame insertion resulting in type 2A were also identified. Of 15 type 3 VWD IC, 13 were homozygous and two compound heterozygous for 14 candidate mutations predicted to result in lack of expression and two propeptide missense changes. Identification of intronic breakpoints of an exon 17–18 deletion suggested that the mutation resulted from non-homologous end joining. This study provides further insight into the pathogenesis of VWD in a population with a high degree of consanguineous partnerships.

Keywords

Large-scale deletion - multiplex ligation-dependent probe amplification - mutation analysis - recessive 2A - von Willebrand disease

• References

• 1 Sadler JE, Budde U, Eikenboom JCJ. et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 04: 2103-2114.
• 2 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987; 69: 454-459.
• 3 Werner EJ, Broxson EH, Tucker EL. et al. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-898.
• 4 Sadler JE. Von Willebrand disease type 1: a diagnosis in search of a disease. Blood 2003; 101: 2089-2093.
• 5 Gupta PK, Ahmed RPH, Sazawal S. et al. Relatively high frequency of VWD types 3 and 2 in a cohort of Indian patients: the role of multimeric analysis. J Thromb Haemost 2005; 03: 1321-1322.
• 6 El-Bostany EA, Omer N, Salama EE. et al. The spectrum of inherited bleeding disorders in pediatrics. Blood Coagul Fibrinolysis 2008; 19: 771-775.
• 7 Donbak L. Consanguinity in Kahramanmaras city, Turkey, and its medical impact. Saudi Med J 2004; 25: 1991-1994.
• 8 Akbayram S, Sari N, Akgün C. et al. The frequency of consanguineous marriage in Eastern Turkey. Genet Couns 2009; 20: 207-214.
• 9 Allen S, Abuzenadah AM, Blagg JL. et al. Two novel type 2N von Willebrand disease-causing mutations that result in defective factor VIII binding, multimerization, and secretion of von Willebrand factor. Blood 2000; 95: 2000-2007.
• 10 Ingerslev J, Stenbjerg S, Taaning E. A case of Bernard-Soulier syndrome: study of platelet glycoprotein Ib in a kindred. Eur J Haematol 1987; 39: 182-184.
• 11 Bukh A, Ingerslev J, Stenbjerg S. et al. The multimeric structure of plasma F VIII:RAg studied by electroelution and immunoperoxidase detection. Thromb Res 1986; 43: 579-584.
• 12 Peake IR, Bowen D, Bignell P. et al. Family studies and prenatal diagnosis in severe von Willebrand disease by polymerase chain reaction amplification of a variable number tandem repeat region of the von Willebrand factor gene. Blood 1990; 76: 555-561.
• 13 Ploos van Amstel HK, Reitsma PH. Tetranucleotide repeat polymorphism in the vWF gene. Nucleic Acids Res 1990; 18: 4957.
• 14 Allen S, Abuzenadah AM, Hinks J. et al. A novel von Willebrand disease-causing mutation (Arg273Trp) in the von Willebrand factor propeptide that results in defective multimerization and secretion. Blood 2000; 96: 560-568.
• 15 Schouten JP, McElgunn CJ, Waaijer R. et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
• 16 Budde U, Schneppenheim R, Eikenboom J. et al. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008; 06: 762-771.
• 17 Tavtigian SV, Deffenbaugh AM, Yin L. et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 2006; 43: 295-305.
• 18 Adzhubei IA, Schmidt S, Peshkin L. et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 07: 248-249.
• 19 Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001; 11: 863-874.
• 20 Houdayer C, Dehainault C, Mattler C. et al. Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat 2008; 29: 975-982.
• 21 Larkin MA, Blackshields G, Brown NP. et al. Clustal W and Clustal X version 2.0. Bioinformatics 2007; 23: 2947-2948.
• 22 Allen S, Goodeve AC, Peake IR. et al. Endoplasmic reticulum retention and prolonged association of a von Willebrand’s disease-causing von Willebrand factor variant with ERp57 and calnexin. Biochem Biophys Res Commun 2001; 280: 448-453.
• 23 Michaux G, Hewlett LJ, Messenger SL. et al. Analysis of intracellular storage and regulated secretion of 3 von Willebrand disease-causing variants of von Willebrand factor. Blood 2003; 102: 2452-2458.
• 24 Caron C, Mazurier C, Goudemand J. Large experience with a factor VIII binding assay of plasma von Willebrand factor using commercial reagents. Br J Haematol 2002; 117: 716-718.
• 25 VWFdb. International Society on Thrombosis and Haemostasis Scientific and Standardization Committee VWF Information Homepage. Available at: www.vwf.group.shef.ac.uk Accessed June 30, 2011.
• 26 Enayat MS, Guilliatt AM, Surdhar GK. et al. A new candidate missense mutation (Leu 1657 Ile) in an apparently asymptomatic type 2A (phenotype IIA) von Willebrand disease family. Thromb Haemost 2000; 84: 369-373.
• 27 Haberichter SL, Budde U, Obser T. et al. The mutation N528S in the von Willebrand factor (VWF) propeptide causes defective multimerization and storage of VWF. Blood 2010; 115: 4580-4587.
• 28 Eikenboom JCJ, Castaman G, Vos HL. et al. Characterization of the genetic defects in recessive type 1 and type 3 von Willebrand disease patients of Italian origin. Thromb Haemost 1998; 79: 709-717.
• 29 Baronciani L, Cozzi G, Canciani MT. et al. Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. Blood Cells Mol Dis 2003; 30: 264-270.
• 30 Shahbazi S, Mahdian R, Ala FA. et al. Molecular characterization of Iranian patients with type 3 von Willebrand disease. Haemophilia 2009; 15: 1058-1064.
• 31 Eikenboom JCJ, Castaman G, Kamphuisen PW. et al. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002; 87: 252-257.
• 32 Eikenboom J, Federici AB, Dirven RJ. et al. VWF propeptide and ratios between VWF, VWF propeptide and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121: 2336-2339.
• 33 The Human Gene Mutation Database (HGMD). Available at: www.hgmd.cf.ac.uk Accessed November 14, 2012.
• 34 The International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007; 449: 851-861.
• 35 The 1000 Genomes Project Consortium. An integrated map of genetic variation from 1,092 human genomes. Nature 2012; 491: 56-65.
• 36 Bellissimo DB, Christopherson PA, Flood VH. et al. VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood 2012; 119: 2135-2140.
• 37 Eikenboom J, Hilbert L, Ribba AS. et al. Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost 2009; 07: 1304-1312.
• 38 Baronciani L, Federici AB, Cozzi G. et al. Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease. J Thromb Haemost 2007; 05: 282-288.
• 39 Smith NL, Chen M-H, Dehghan A. et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. Circulation 2010; 121: 1382-1392.
• 40 Hickson N, Hampshire D, Castaman G. et al. Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. J Thromb Haemost 2011; 09: 603-605.
• 41 Xie F, Wang X, Cooper DN. et al. Compound heterozygosity for two novel mutations (1203insG/Y1456X) in the von Willebrand factor gene causing type 3 von Willebrand disease. Haemophilia 2007; 13: 645-648.
• 42 Yadegari H, Driesen J, Pavlova A. et al. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients. Thromb Haemost 2012; 108: 662-671.
• 43 Goodeve AC. The genetic basis of von Willebrand disease. Blood Rev 2010; 24: 123-134.
• 44 Hampshire DJ, Goodeve AC. The molecular basis of von Willebrand disease: the under investigated, the unexpected and the overlooked. Haematologica 2011; 96: 798-800.
• 45 Castaman G, Giacomelli SH, Mancuso ME. et al. Deep intronic variations may cause mild hemophilia A. J Thromb Haemost 2011; 09: 1541-1548.
• 46 Goodeve A, Eikenboom J, Castaman G. et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 vonWillebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 vonWillebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112-121.
• 47 Gu W, Zhang F, Lupski JR. Mechanisms for human genomic rearrangements. Pathogenetics 2008; 01: 4.
• 48 Zimmermann MA, Oldenburg J, Müller CR. et al. Characterization of duplication breakpoints in the factor VIII gene. J Thromb Haemost 2010; 08: 2696-2704.
• 49 Abeysinghe SS, Chuzhanova N, Krawczak M. et al. Translocation and gross deletion breakpoints in human inherited disease and cancer I: nucleotide composition and recombination-associated motifs. Hum Mutat 2003; 22: 229-244.
• 50 Vissers LELM, Bhatt SS, Janssen IM. et al. Rare pathogenic microdeletions and tandem duplications are microhomology-mediated and stimulated by local genomic architecture. Hum Mol Genet 2009; 18: 3579-3593.